Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Gaudium IVF and Women Health Ltd (GAUDIUMIVF)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544709 NSE: GAUDIUMIVF Hospital & Healthcare Services | Small Cap | Gaudium IVF & Women Share Price
₹118.50 4.00 (3.49%)
As on 11-Sep'26 16:01
Gaudium IVF and Women Health Ltd (GAUDIUMIVF)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544709 NSE: GAUDIUMIVF Hospital & Healthcare Services | Small Cap | Gaudium IVF & Women Share Price
₹118.50 4.00 (3.49%)
As on 11-Sep'26 16:01
Key Metrics
Valuation Multiples
Market Cap
₹833 Cr.
Current Price
₹118.5
52-Week Low / High
₹70 / 164
TTM EPS
₹3.4
TTM Sales
₹104 Cr.
Book Value per Share
₹21.2
P/E Ratio
34.07
Lower than its 5-year historical median
Industry PE
100.8
Price to Book (P/B)
5.41
Lower than its 5-year historical median
Price to Sales (P/S)
7.99
Lower than its 5-year historical median
EV/EBITDA
22.17
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
52.20%
Outperforms industry median
Return on Capital Employed (ROCE)
50.15%
Outperforms industry median
Return on Assets (ROA)
27.42%
Operating Profit Margin
41%
Net Profit Margin
27.05%
Gross Profit Margin
38.8%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
28.43%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
48.56%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
85.37%
Asset Quality
Promoter Holding
71.29%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹118 Cr.
Equity
₹36.4 Cr.
Face Value
₹5
All Time Low / High
₹69.50 / 163.70
Check Before You Invest
Quality
Somewhat GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Weak
Is Gaudium IVF and Women Health Ltd a good quality company?
Gaudium IVF and Women Health Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Gaudium IVF and Women Health Ltd performance compare with that of its Peers?
Revenue growth of Gaudium IVF and Women Health Ltd vs industry peers?
Gaudium IVF and Women Health Ltd revenue CAGR is 17.34%, compared to the industry median CAGR of 10.53%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Gaudium IVF and Women Health Ltd?
Promoters hold 71.29% of the Gaudium IVF and Women Health Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Gaudium IVF and Women Health Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gaudium IVF and Women Health Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 82.7% | 76.5% | 45.4% | 49.3% | - |
| Value Creation Index ⓘ | 4.9 | 4.5 | 2.2 | 2.5 | - |
Growth Parameters ⓘ |
|||||
| Sales ⓘ | 36.5 | 44 | 45.9 | 59 | 72 |
| Sales YoY Gr. | - | 20.5% | 4.4% | 28.4% | - |
| Adj EPS ⓘ | 1.5 | 2.2 | 1.6 | 3 | 3.1 |
| YoY Gr. | - | 46% | -25% | 87% | - |
| BVPS (₹) ⓘ | 1.6 | 3.7 | 4.3 | 7.4 | 20.7 |
| Adj Net Profit ⓘ | 9.1 | 13.3 | 9.9 | 18.6 | 22 |
| Cash Flow from Ops. ⓘ | 0 | 24 | 3.5 | 8.4 | - |
| Debt/CF from Ops. ⓘ | 0 | 0.4 | 4.5 | 2.2 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 17.3% | 28.4% | ||||
| Adj EPS ⓘ | NA | NA | 27% | 87% | ||||
| BVPSⓘ | NA | NA | 68% | 70.5% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 95.1 | 81.9 | 40.1 | 51.6 | 21.8 |
| Op. Profit Mgn % ⓘ | 37.8 | 44.9 | 41.1 | 47.6 | 37.6 |
| Net Profit Mgn % ⓘ | 24.9 | 30.1 | 21.6 | 31.5 | 31.1 |
| Debt to Equity ⓘ | 0.6 | 0.4 | 0.6 | 0.4 | - |
| Working Cap Days ⓘ | 0 | 75 | 91 | 175 | 61 |
| Cash Conv. Cycle ⓘ | 0 | 13 | 49 | 107 | 33 |
Valuation of Gaudium IVF & Women - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|
| Sales | 37 | 44 | 48 | 71 |
| Operating Expenses ⓘ + | 23 | 24 | 28 | 42 |
| Operating Profit ⓘ | 14 | 20 | 19 | 29 |
| Operating Profit Margin (%) | 37.0% | 45.7% | 40.6% | 40.8% |
| Other Income ⓘ + | 0 | 0 | 0 | 0 |
| Interest ⓘ | 1 | 0 | 1 | 2 |
| Depreciation ⓘ | 1 | 1 | 2 | 2 |
| Profit Before Tax ⓘ | 12 | 18 | 17 | 25 |
| Tax ⓘ | 3 | 5 | 6 | 6 |
| Profit After Tax | 9 | 14 | 10 | 19 |
| PAT Margin (%) | 24.2% | 30.6% | 21.5% | 27.1% |
| Adjusted EPS (₹) | 1.4 | 2.2 | 1.7 | 3.1 |
| Dividend Payout Ratio (%) | 0% | 47% | 0% | 0% |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 9 | 23 | 27 | 46 | |||||||
| Debt + | 6 | 10 | 16 | 19 | |||||||
| Minority Interest | 0 | 0 | 0 | 0 | |||||||
| Trade Payables | 1 | 1 | 1 | 14 | |||||||
| Others Liabilities ⓘ | 1 | 3 | 8 | 9 | |||||||
| Total Liabilities ⓘ | 18 | 37 | 51 | 89 | |||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 4 | 18 | 19 | 18 | |||||||
| CWIP ⓘ | 0 | 0 | 0 | 7 | |||||||
| Investments ⓘ | 0 | 0 | 0 | 5 | |||||||
| Inventories | 0 | 1 | 2 | 7 | |||||||
| Trade Receivables | 6 | 1 | 14 | 33 | |||||||
| Cash Equivalents | 2 | 15 | 12 | 7 | |||||||
| Others Assets ⓘ | 5 | 1 | 5 | 11 | |||||||
| Total Assets ⓘ | 18 | 37 | 51 | 89 | |||||||
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -1 | 24 | 3 | 9 |
| Cash Flow From Investing Activity ⓘ + | -1 | -16 | -5 | -15 |
| Cash Flow From Financing Activity ⓘ + | 3 | 5 | -1 | 2 |
| Net Cash Flow ⓘ | 0 | 13 | -3 | -5 |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 94.99 | 84.47 | 41.5 | 52.2 | ||||||
| ROCE (%) | 82.39 | 78.74 | 46.65 | 50.15 | ||||||
| Asset Turnover Ratio | 2.08 | 1.63 | 1.09 | 1.01 | ||||||
| PAT to CFO Conversion(x) | -0.11 | 1.71 | 0.3 | 0.47 | ||||||
| Working Capital Days | ||||||||||
| Receivable Days | 64.90 | 30.50 | 55.30 | 119.90 | ||||||
| Inventory Days | 3.40 | 7.60 | 13.70 | 24.10 | ||||||
| Payable Days | 114.10 | 87.50 | 72.30 | 178.10 | ||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Gaudium IVF and Women Health Ltd FAQs
The current trading price of Gaudium IVF & Women on 11-Sep-2026 16:01 is ₹118.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Gaudium IVF & Women stood at ₹833.4 Cr
The latest P/E ratio of Gaudium IVF & Women as of 10-Sep-2026 is 37.39.
The latest P/B ratio of Gaudium IVF & Women as of 10-Sep-2026 is 5.52.
The 52-week high of Gaudium IVF & Women is ₹163.7 and the 52-week low is ₹69.50.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gaudium IVF & Women is ₹71.58 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Gaudium IVF and Women Health Ltd is a average quality company.
The key valuation ratios of Gaudium IVF and Women Health Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gaudium IVF and Women Health Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Gaudium IVF and Women Health Ltd
Gaudium IVF and Women Health was originally incorporated in the name of ‘Gaudium IVF and Women Health Private Limited’ as a private limited company on March 24, 2015. Subsequently, the company was converted from a private limited company into a public limited company pursuant to a special resolution passed in the extraordinary general meeting of the shareholders held on September 28, 2024 and consequently, the name of the company was changed to ‘Gaudium IVF and Women Health Limited’.
The company is engaged in IVF (In vitro fertilization) treatment in India and has grown into several states with Hub and spoke model over the years. The company has patients from different countries such as Canada, United Kingdom, United State, Kenya, South Africa and Oman. The company’s Main centers (Hubs) are located in major cities to cater potential locations across India.
The company offers a complete array of specialized fertility and reproductive health services. Its advance treatments include In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction, all its treatments are carefully designed to address a variety of infertility challenges for both male and female. The company also offers comprehensive gynaecological care, including PCOD/PCOS and endometriosis. Further, high-risk pregnancy management is provided for women with complex fertility histories or health conditions. The wellness aspect includes fertility wellness programs, offering nutritional counselling and psychological support to ensure holistic care for couples undergoing treatments.
Business area of the company
The company is engaged in IVF (In vitro fertilization) treatment in India and has grown into several states with Hub and spoke model over the years. The company has patients from different countries such as Canada, United Kingdom, United State, Kenya, South Africa and Oman. The company’s Main centers (Hubs) are located in major cities to cater potential locations across India.
Services of the company
Fertility Treatment
- IVF treatment, or in vitro fertilization
- Intrauterine Insemination (IUI)
- Intracytoplasmic Sperm Injection (ICSI)
- Polycystic Ovarian Syndrome (PCOS), also known as polycystic ovarian disease (PCOD)
- Male Infertility
- Endometriosis Treatment
- Ovulation Induction (OI)
- Laser Assisted Embryo Implantation
- Infertility Surgeries
- Surrogacy
Hospital Facility
Pharmacy service
Awards, accreditations and recognition
- 2016: Asia's Greatest Brand.
- 2018: Symbol of Brand Excellence Award.
- 2019: India Best Practices Award- IVF Chain Company of the Year.
- 2022: Highly Prestigious Quality Choice Award.
- 2023: Holistic Healthcare Brand Leader of the Year.
History and milestones
- 2015: Incorporation of the company.
- 2019: The company started Gaudium Hospital.
- 2021: Acquired the Gaudium IVF & Gynae Solutions, Proprietor Business of Dr. Manika Khanna: Janakpuri Center (opened in 2009), Greater Kailash Center (opened in 2016), Patna Center (opened in 2019).
- 2021: The company started Mumbai Center (Maharashtra).
- 2023: Acquired Gaudium Brand.
- 2023: Acquired 100% shares of Gaudium International Private Limited.
- 2023: Acquired Gaudium Bawa Ludhiana Center.
- 2023: The company started Bangalore Centre (Karnataka).
- 2024: The company started Srinagar Centre (Jammu & Kashmir).
- 2024: Conversion of company from Private to Public.
You have 36 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
